TITLE

Novel drug promotes weight loss, reduces obesity-related risks

AUTHOR(S)
Portyansky, Elena
PUB. DATE
May 1999
SOURCE
Drug Topics;5/17/99, Vol. 143 Issue 9, p27
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Focuses on Xenical, an antiobesity drug from Hoffmann-La Roche. Weight-loss benefits of orlistat; Side-effects of the drug; Information on minimizing the drug's side-effects. INSET: Tips to Remember.
ACCESSION #
1934354

 

Related Articles

  • Fighting fat.  // Drug Topics;6/2/97, Vol. 141 Issue 11, p30 

    Reports on the US Food and Drug Administration's approval of Hoffmann-La Roche's anti-obesity drug Xenical.

  • Roche resubmits Xenical NDA in face of phen-fen legal action.  // Medical Marketing & Media;Dec97, Vol. 32 Issue 12, p24 

    Reports that Hoffmann-La Roche has resubmitted its new drug application for the anti-obesity drug Xenical or orlistat at the US Food and Drug Administration. Mechanism of action of Xenical; Recall of the anti-obesity drugs Pondimin and Redux.

  • New Accutane studies surface in wake of $70 million lawsuit against Roche. Troy, Timothy N. // Dermatology Times;Jun2002, Vol. 23 Issue 6, p6 

    Reports the initiation of a study on the association of Accutane from Hoffman-La Roche Inc. with causal trigger for depression and suicide in the U.S. Focus of the study; Amount of lawsuit alleged to La Roche; Views of Donald H. Marks, a clinical research expert on the adverse effects of Accutane.

  • Legal aid won for malaria drug case. Dyer, Clare // BMJ: British Medical Journal (International Edition);9/14/96, Vol. 313 Issue 7058, p643 

    Reports on the investigation of the effectiveness of the malarial drug mefloquine, which will serve as the basis of the Legal Aid Board's decision on the filing of a case against the drug manufacturer Hoffmann-La Roche Inc. Adverse effects of Lariam; Includes panic attacks; Depression and fits.

  • Orlistat approved.  // Healthy Weight Journal;Sep/Oct1999, Vol. 13 Issue 5, p66 

    Reports on the approval of the drug orlistat from Roche Laboratories for the treatment of obesity. Efficacy of the drug; Side effects of the drug.

  • Fat-Blocking Drug Can Help Fight Obesity.  // FDA Consumer;Jul/Aug99, Vol. 33 Issue 4, p2 

    Reports on the anti-obesity Xenical made by Roche Laboratories Inc. that works by blocking the body's absorption of fat. Results of the long-term clinical trials on the lipase inhibitor; Diet of a patient during treatment; Common side effects of the drug.

  • Roche Looks for New Spin on Xenical.  // Pharmaceutical Executive;May2000, Vol. 20 Issue 5, p154 

    Announces the search of Hoffman-La Roche for an advertising agency to promote its antiobesity drug Xenical. Revenues generated by sales of the drug for the first quarter of 2000; Advertising expenditures of the company for the drug; Media buys that the company initiated.

  • Roche picks Lowe shops for new anti-obesity drug. Gleason, Mark; Wilke, Michael // Advertising Age;10/14/1996, Vol. 67 Issue 42, p60 

    Tells that Roche Laboratories chose a team of advertising agencies to handle the launch of a new prescription anti-obesity treatment. Roche's orlistat, to be marketed under the name Xenical; Aggressive marketing plan; Pending approval from the US Food & Drug Administration; Comparision to other...

  • Accutane faces new lawsuit. Troy, Timothy N. // Dermatology Times;May2002, Vol. 23 Issue 5, p1 

    Reports the lawsuit filed against Hoffman-La Roche Inc., makers of the Accutane drug in the U.S. Details on the suicide death of teenager Charles Bishop; Associations between Accutane side effects with depressive and suicidal behavior; Criticisms on the forensic testing of the case.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics